Standout Papers
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (2019)
- Efficacy of Wolbachia-mediated sterility to reduce the incidence of dengue: a synthetic control study in Singapore (2024)
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020)
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study (2017)
Citation Impact
2 by Nobel laureates 1 from Science/Nature 76 standout
Citing Papers
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Works of Caleb Lee being referenced
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020 Standout
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2017 Standout
Author Peers
| Author | Oncology | PHEOH | RNMI | PRM | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Caleb Lee | 1205 | 171 | 639 | 513 | 28 | 1.6k | |
| Francis Westley | 1 | 6 | 41 | ||||
| G. Archbold | 3 | 15 | |||||
| Annette Raffan | 1 | 1 | 9 | 461 | |||
| J.D. Hurley | 1 | 12 | 183 | ||||
| C. D. Wheeler | 2 | 9 | 130 |
All Works
Login with ORCID to disown or claim papers
Loading papers...